Novartis: Sandoz applies for blood cancer drug biosimilar.

(CercleFinance.com) - Sandoz said on Tuesday that it has applied to the US FDA for approval to sell its version of Biogen's Rituxan, a treatment for blood cancers.


The Novartis unit said that the Food and Drug Administration has accepted its biologics license application (BLA).

Rituxan is used to treat blood cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.

Copyright (c) 2017 CercleFinance.com. All rights reserved.